Immuneering Co. (NASDAQ:IMRX - Get Rating) - Equities researchers at Oppenheimer lowered their Q2 2022 EPS estimates for Immuneering in a research note issued to investors on Wednesday, May 11th. Oppenheimer analyst M. Breidenbach now expects that the company will earn ($0.52) per share for the quarter, down from their previous estimate of ($0.46). Oppenheimer has a "Outperform" rating and a $25.00 price objective on the stock. Oppenheimer also issued estimates for Immuneering's Q3 2022 earnings at ($0.55) EPS, Q4 2022 earnings at ($0.58) EPS, FY2022 earnings at ($2.14) EPS, Q1 2023 earnings at ($0.61) EPS, Q2 2023 earnings at ($0.64) EPS, Q3 2023 earnings at ($0.65) EPS, Q4 2023 earnings at ($0.47) EPS, FY2023 earnings at ($2.32) EPS, FY2024 earnings at ($2.11) EPS, FY2025 earnings at ($2.40) EPS and FY2026 earnings at ($2.36) EPS.
Separately, Zacks Investment Research cut Immuneering from a "buy" rating to a "hold" rating in a research note on Friday. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $29.13.
NASDAQ:IMRX opened at $5.03 on Monday. Immuneering has a one year low of $4.11 and a one year high of $33.99. The business's 50-day simple moving average is $6.38 and its 200 day simple moving average is $13.32. The stock has a market cap of $132.72 million and a price-to-earnings ratio of -1.68. Immuneering (NASDAQ:IMRX - Get Rating) last issued its quarterly earnings data on Thursday, March 10th. The company reported ($0.42) EPS for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.03). The company had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.60 million. Immuneering had a negative return on equity of 38.00% and a negative net margin of 21.73%.
Several institutional investors have recently modified their holdings of the stock. Citadel Advisors LLC acquired a new position in shares of Immuneering in the 3rd quarter valued at $52,403,000. BlackRock Inc. acquired a new position in shares of Immuneering during the 3rd quarter worth approximately $40,472,000. Rock Springs Capital Management LP bought a new stake in shares of Immuneering during the 3rd quarter worth approximately $28,935,000. Perceptive Advisors LLC bought a new stake in shares of Immuneering during the 3rd quarter worth approximately $18,082,000. Finally, Vanguard Group Inc. increased its position in shares of Immuneering by 158.8% during the first quarter. Vanguard Group Inc. now owns 812,392 shares of the company's stock worth $5,256,000 after buying an additional 498,479 shares during the period. 47.41% of the stock is owned by institutional investors and hedge funds.
In other Immuneering news, Director Ann E. Berman bought 6,000 shares of the stock in a transaction on Tuesday, March 15th. The shares were purchased at an average cost of $6.40 per share, with a total value of $38,400.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders bought 10,900 shares of company stock worth $73,621 over the last ninety days.
About Immuneering (Get Rating)
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider Immuneering, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immuneering wasn't on the list.
While Immuneering currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The 5 Stocks Here